Raymond James Hires Biotechnology Sector Analyst Danielle Brill
ST. PETERSBURG, Fla. – Raymond James has hired Danielle Brill as a biotechnology research analyst in the firm’s Equity Research department. Brill will cover biopharma companies that focus on neurology, hematology and autoimmune diseases. She joins the firm’s existing research analysts focused on the biotechnology sector: Dane Leone, Steve Seedhouse and David Novak, as well as Elliot Wilbur, who covers specialty pharmaceuticals.
Brill has more than a decade of combined experience in the pharmaceutical industry and as a biopharma research analyst. She joins Raymond James from Piper Sandler and was previously with Needham & Co. Prior to transitioning to finance, Brill was a clinical pharmacist at a major specialty pharmaceutical company and a senior research technician at both Columbia University Medical Center and New York University. Brill holds a Bachelor of Science in human biology from Michigan State University and a Doctorate of Pharmacy from Rutgers University.
“Danielle is a talented analyst who consistently earns praise from clients for her objectivity, even temperament and investment acumen,” said Brian Alexander, director of Equity Research. “Her education and background as a clinical pharmacist give her a unique perspective into biopharma companies which translates into insightful and thorough research. We’re thrilled to welcome her to our highly competitive Life Sciences franchise.”
Brill is based in the firm’s New York office.
About Raymond James Financial, Inc.
Raymond James Financial, Inc. (NYSE: RJF) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. The company has approximately 8,100 financial advisors. Total client assets are $858 billion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com.